Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 SOLANA BEACH, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
Encouraging early traction from GIMOTI™ commercial launch SOLANA BEACH, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3 Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare professionals SOLANA BEACH, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif. , March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M , a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
SOLANA BEACH, Calif. , March 25, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013 .
SOLANA BEACH, Calif., March 4, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2014.
80% increase in GIMOTI ® net revenue over Q2 2022 56% increase of GIMOTI prescription fills in Q3 compared to Q2 13% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
SOLANA BEACH, Calif. , Aug. 13, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014 .
